{"name":"Hims & Hers Health","slug":"hims","ticker":"HIMS","exchange":"NYSE","domain":"forhims.com","description":"Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products.","hq":"San Francisco, CA","founded":2017,"employees":"2442","ceo":"Andrew Dudum","sector":"Telehealth & Consumer Health","stockPrice":19.78,"stockChange":0.28,"stockChangePercent":1.44,"marketCap":"$4.5B","metrics":{"revenue":2347637000,"revenueGrowth":28.4,"grossMargin":73.8,"rdSpend":0,"netIncome":128365000,"cash":577491968,"dividendYield":0,"peRatio":40.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Finasteride patent cliff ($1.2B at risk)","drug":"Finasteride","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Sildenafil patent cliff ($0.8B at risk)","drug":"Sildenafil","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Hims & Hers Health Reports Q4 2023 Earnings","summary":"Hims & Hers Health reported Q4 2023 earnings, with revenue of $143.4 million and a net loss of $23.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Hims & Hers Health Partners with Walgreens to Expand Access to Telehealth Services","summary":"Hims & Hers Health partnered with Walgreens to expand access to telehealth services, allowing customers to access HIMS' services through Walgreens' pharmacies.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQajUtM2l2VFVjVk5KVE9Xd3RySzhSX1RjQzc4NHVjMkExVTRYM1B6bi1hdWtKczlXQkJtWTBGYU8yckFtQ2dZOS0ta3h6SnFybTFSWENSWm4yaklfeTVIZndLX1lucW9hNmpiWERxRWRnUmVjbG54RFNMZ0w0R0I0NmQtWUVNVVFCYVVsQlVjN2U2R0tQQ2ZzRjlFeVNwMkdhRTEyUw?oc=5","date":"2026-04-03","type":"pipeline","source":"Yahoo Finance","summary":"Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance","headline":"Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxPeDFRNUszQ0FTZFN0U251Mm1EUlBjX2U1MDU1NXRzYTI2WjNlc2lVMGh1UkZocjVqem5tYWlyZWRPejhTRHZQSDdQQkd3Zjc1dVZ1a2ZwVmlHWkhZOXpHN0dGU1dpaXJxTmVhMWhSODRpNm8tbVdVSWFfNmpnb1NDT3ZoZTNHZmdDVXlDckVsNGsyVWN5ZFB2RmloOWJGdjJIUGJPaXIwLUVJUXBaWC1hNjYteTVpeFRyNmppVldCOEQ0LTMyMmo5eE5ielN4ZzBvTnVZWGp4X19DNzB1UVBsYWN5WVdDRjI3?oc=5","date":"2026-03-12","type":"pipeline","source":"FinancialContent","summary":"The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot - FinancialContent","headline":"The New Era of Hims & Hers Health (HIMS): Navigating the Branded Obesity Drug Pivot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPOWRNQk5talFGMDhvOVE2SEQzVmt6WkNISUxqTTQyU3NuZDZNeVBfTmlxdWcxQkNrb0N0cWc3azdnR1kwQjBGS1pteFNoSEVnSTRJWjdfUlRJNXJhZGpCelJVaUEzaE1CLWMtLW9ZVDdGRUhVQ1Z0Q19lcUxHeGVFT0xn?oc=5","date":"2026-03-09","type":"pipeline","source":"Barron's","summary":"Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. - Barron's","headline":"Hims & Hers Stock Soars. Its Weight-Loss Drug Battle With Novo Nordisk Takes a Surprising Twist. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPejBjN1J4OVlSc1B5enlWbXdjbC1VaDh0UGd2Mk1GUno5Uk1ZY0RaUzZkOExkY2NjVkpQRFlVWG9hdVhCMFlSdkJKSF8xdEtGaTFHNDdNSF9hdlVFUVFmYVBPU1RmZ0J5Z2pxaXF6Yk1xZWUtUzVacVhXM2VZeDFWWkpZTHZ5T0l5?oc=5","date":"2026-02-19","type":"deal","source":"pharmaphorum","summary":"Hims & Hers buys Australian digital health firm for $1.15bn - pharmaphorum","headline":"Hims & Hers buys Australian digital health firm for $1.15bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOelFWVGJhQ1htc1hRUDlEWGoyWnFRdXQzY3pRVEstZWNsd01JaTZCVG83d1RZUlVEdjdOZmY3bm9FTFJmRk5nSnNSRldSODVPRXZiNHNzWWVsMlRhN0dqY1ZIUFFpbGNoVTduUUJzV1NlN3dEVERnRmJZNnFvU0EtbHh2NGlvcWRWZEN5dHJrUV8tN3c?oc=5","date":"2026-02-11","type":"pipeline","source":"Seeking Alpha","summary":"Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha","headline":"Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNVEJ0NTJlOGJ0X3dKeVpCRHVjWjJJSEpUOElnU0hIZGphNXAzbk5JVFZrYjlvUUpUSkhES01JbFJ1ME16RFkwUmxYcHg3cGNNYjRkTzdkR28tZXQzb2xQMGR4Vy16MmFoQ0ZmanMtbXE5MXhxdUJoWVZaYkxZZzVVYXh1WVlnelI3bS05V1NOcnZ1ZGJHVVlva3BfUEhlVEU?oc=5","date":"2026-02-09","type":"regulatory","source":"Fierce Pharma","summary":"Hims retreats from weight loss pill launch as Novo, FDA pressure mounts - Fierce Pharma","headline":"Hims retreats from weight loss pill launch as Novo, FDA pressure mounts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQTHRWVThHYW0tMkkzMjQxN3VuVkF6RzNicV9KLWFuSU9oREc0bmNuRkpoWlhsMWJFVzN1U1NRc3lmQ1VMOUZlSWxYMFhobjNkbXVGUHZ6YURfZ0JTQ3pCTFFLT2tkTWtiUlVwT2FTRlo5U3oxbzRDY3hJRUZldXhHbzBSVXNiN0NXLXp0M0lXQnJCWThJaXc?oc=5","date":"2026-02-09","type":"pipeline","source":"The Washington Post","summary":"Hims & Hers in hot water - The Washington Post","headline":"Hims & Hers in hot water","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQS3oyNkhPRzY2bE5LSm9xT01OYjZ2aGZhamVMdldYWjZfbF9aU21DbWthQ0VRdFNLZldvMHc4aFU0X2FiLW00X1ZSSVg5RFMtUXBOQjZuY2p3RC10WmNUc3k0aTI0bWdwM0l4aUF2OW1PQVFQem03RlpZRzZLR1B5ajNIN0FoMFFjTlRpdFR1R2ExRHNlYWl0N0s1WDc0aWZZVnlkZWJn?oc=5","date":"2026-02-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"Novo sues Hims & Hers despite Wegovy pill offering U-turn - Pharmaceutical Technology","headline":"Novo sues Hims & Hers despite Wegovy pill offering U-turn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPUENTTG41bVRyRUNmS2p3N2JHQURZWVZkb1lfQU9mZDlvSEhIWkZ5dVo0WnRRN0pCQnFVZEtHanY2ZzBybDh0ZTZxaWhCVzg5TXR4VXp2R3l2MUJYMnVUTGJfUmRubUFOOF9MOXFnLTgxU0hHbWtqYkJCemtWOXJEOFNfaG5NSGxFYU1TckhXSk8xTTlwNnZpWXlUX1lvdmg5N0FuMjMyTF9Ebm9QQ2ZVaDBqZzB0VVps?oc=5","date":"2026-02-06","type":"pipeline","source":"Reuters","summary":"Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly - Reuters","headline":"Exclusive: Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPdGRjY0M5M1RqTWFhVzBHUU1QNEhWYXVRaXFtNEMxc251WWpLT0ZNZUFzME9mbEh3Rk9yRHU1WlpaWlhJNjFKZ2piaU03ZThMakh0Q0QxNy1QcWtVbU5HOWpaa2ZCQlU0cS01M19BRGd5c0RhQkxhUEN3RzZ5NGhUNnlnSXRPOS1HdExKN1NWVzBkTy1DbWktZFEwbUlXTmZRNTF0QlBVS2lfOFZObTA4enhtVFQxRTBMMWc?oc=5","date":"2026-02-06","type":"pipeline","source":"WSJ","summary":"Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department - WSJ","headline":"Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOVlNPNXFISFBxTmd4ZmtNci1aTHhhWVJDVGRWUElnQ3E3Z1lIMDBZQ0g1c2xjSHRRMjdlZXc4cGRRZ1ppaDMtSlFzQkJJc2E2Yk5uTG1jV1FmRi1DTjAzNGM2MWVuOHpvbXVsRlpJSk5OU3VqeTZXNE5fS1J5V3ZuS3RsRFNnemUyTXpQc09Wb2xGMHBSZTNsRHFjUG1jWUt4ZnV6dFRaWGhrcnlRRnZsaUtxcUo?oc=5","date":"2026-02-06","type":"regulatory","source":"bloomberg.com","summary":"FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals (HIMS) - bloomberg.com","headline":"FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals (HIMS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPWWFka0dNX1ZzVGwxSHp0NGZlYUxhMFpZb1ZfNGFsbzdiekhubjNGVmNpQm5qWnYtRjhuMWxhSXV1eFR0SnlWM1h5Q19WVFloU1RaZzJqbFJhVndGcXlteGlzRW5WdW04YU1yRVE3ME5UaklHSnNpN0Z3OTJDaTRLMG5sdEg5NE5ycHBsZlZXWFFvdFktSGVBQk1zNEJfbTRmZjlUTTQ3TjJqbVhKMzNuTDVSWXpHSENTNkh5ZnZCTGRLczVlRkRHWWln?oc=5","date":"2026-01-09","type":"pipeline","source":"Investing.com","summary":"Hims & Hers Health stock falls after Amazon Pharmacy adds Wegovy pill - Investing.com","headline":"Hims & Hers Health stock falls after Amazon Pharmacy adds Wegovy pill","sentiment":"neutral"}],"patents":[{"drugName":"Sildenafil","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":800000000},{"drugName":"Finasteride","drugSlug":"finasteride","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Teladoc Health","Amwell","American Well"],"therapeuticFocus":["Men's Health","Women's Health"],"financials":{"source":"sec_edgar","revenue":2347637000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":2347637000,"period":"2025-12-31"},{"value":1476514000,"period":"2024-12-31"},{"value":1476514000,"period":"2024-12-31"},{"value":872000000,"period":"2023-12-31"},{"value":872000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":128365000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":2154705000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":19.78,"previousClose":19.5,"fiftyTwoWeekHigh":70.43,"fiftyTwoWeekLow":13.74,"fiftyTwoWeekRange":"13.74 - 70.43","fiftyDayAverage":20.95,"twoHundredDayAverage":39.59,"beta":2.31,"enterpriseValue":4987904000,"forwardPE":12,"priceToBook":8.31,"priceToSales":1.92,"enterpriseToRevenue":2.12,"enterpriseToEbitda":28.39,"pegRatio":1.65,"ebitda":175659008,"ebitdaMargin":7.5,"freeCashflow":110513624,"operatingCashflow":300006016,"totalDebt":1120589952,"debtToEquity":207.2,"currentRatio":1.9,"returnOnAssets":5.3,"returnOnEquity":25.2,"analystRating":"2.7 - Hold","recommendationKey":"hold","numberOfAnalysts":13,"targetMeanPrice":24.15,"targetHighPrice":30,"targetLowPrice":16,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.7,"institutionHeldPercent":85.6,"sharesOutstanding":219561143,"floatShares":207360454,"sharesShort":83286092,"shortRatio":2.17,"shortPercentOfFloat":36.5,"epsTrailing":0.49,"epsForward":1.65,"revenuePerShare":10.44,"bookValue":2.38,"officers":[{"age":37,"name":"Mr. Andrew  Dudum","title":"Co-Founder, Chairman & CEO"},{"age":38,"name":"Mr. Oluyemi  Okupe","title":"Chief Financial Officer"},{"age":44,"name":"Mr. Mike  Chi","title":"Chief Operating Officer"},{"age":47,"name":"Ms. Soleil Teubner Boughton J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":67,"name":"Dr. Patrick  Carroll M.D.","title":"Chief Medical Officer & Director"},{"age":58,"name":"Ms. Deborah M. Autor J.D.","title":"Chief Policy Officer & Director"},{"age":41,"name":"Ms. Irene A. Becklund","title":"Senior VP, Controller & Principal Accounting Officer"},{"age":50,"name":"Mr. Mohamed  ElShenawy","title":"Chief Technology Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.hims.com","phone":"415 851 0195"}}